Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells

Maura Sonego, Ilenia Pellizzari, Alessandra Dall'Acqua, Eliana Pivetta, Ilaria Lorenzon, Sara Benevol, Riccardo Bomben, Paola Spessotto, Roberto Sorio, Valter Gattei, Barbara Belletti, Monica Schiappacassi, Gustavo Baldassarre

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. However, acquired resistance to platinum occurs frequently and predicts poor prognosis. To understand the mechanisms underlying acquired platinum-resistance, we have generated and characterized three platinum-resistant isogenic EOC cell lines. Resistant cells showed 3-To 5-folds increase in platinum IC50. Cross-resistance to other chemotherapeutic agents commonly used in the treatment of EOC patients was variable and dependent on the cell line utilized. Gene expression profiling (GEP) of coding and non-coding RNAs failed to identify a common signature that could collectively explain the mechanism of resistance. However, we observed that all resistant cell lines displayed a decreased level of DNA platination and a faster repair of damaged DNA. Furthermore, all platinum resistant cell lines displayed a change in their morphology and a higher ability to grown on mesothelium. Overall, we have established and characterized three new models of platinum-resistant EOC cell lines that could be exploited to further dissect the molecular mechanisms underlying acquired resistance to platinum. Our work also suggests that GEP studies alone, at least when performed under basal culture condition, do not represent the optimal way to identify molecular alterations linked to DNA repair pathway defects.

Original languageEnglish
Article number7104
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Platinum
Phenotype
Cell Line
Gene Expression Profiling
DNA Repair
Untranslated RNA
Ovarian epithelial cancer
Standard of Care
Inhibitory Concentration 50
Epithelium
DNA
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. / Sonego, Maura; Pellizzari, Ilenia; Dall'Acqua, Alessandra; Pivetta, Eliana; Lorenzon, Ilaria; Benevol, Sara; Bomben, Riccardo; Spessotto, Paola; Sorio, Roberto; Gattei, Valter; Belletti, Barbara; Schiappacassi, Monica; Baldassarre, Gustavo.

In: Scientific Reports, Vol. 7, No. 1, 7104, 01.12.2017.

Research output: Contribution to journalArticle

@article{4f4451b460b74f9c852a6014dd164f51,
title = "Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells",
abstract = "Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. However, acquired resistance to platinum occurs frequently and predicts poor prognosis. To understand the mechanisms underlying acquired platinum-resistance, we have generated and characterized three platinum-resistant isogenic EOC cell lines. Resistant cells showed 3-To 5-folds increase in platinum IC50. Cross-resistance to other chemotherapeutic agents commonly used in the treatment of EOC patients was variable and dependent on the cell line utilized. Gene expression profiling (GEP) of coding and non-coding RNAs failed to identify a common signature that could collectively explain the mechanism of resistance. However, we observed that all resistant cell lines displayed a decreased level of DNA platination and a faster repair of damaged DNA. Furthermore, all platinum resistant cell lines displayed a change in their morphology and a higher ability to grown on mesothelium. Overall, we have established and characterized three new models of platinum-resistant EOC cell lines that could be exploited to further dissect the molecular mechanisms underlying acquired resistance to platinum. Our work also suggests that GEP studies alone, at least when performed under basal culture condition, do not represent the optimal way to identify molecular alterations linked to DNA repair pathway defects.",
author = "Maura Sonego and Ilenia Pellizzari and Alessandra Dall'Acqua and Eliana Pivetta and Ilaria Lorenzon and Sara Benevol and Riccardo Bomben and Paola Spessotto and Roberto Sorio and Valter Gattei and Barbara Belletti and Monica Schiappacassi and Gustavo Baldassarre",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-07005-1",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells

AU - Sonego, Maura

AU - Pellizzari, Ilenia

AU - Dall'Acqua, Alessandra

AU - Pivetta, Eliana

AU - Lorenzon, Ilaria

AU - Benevol, Sara

AU - Bomben, Riccardo

AU - Spessotto, Paola

AU - Sorio, Roberto

AU - Gattei, Valter

AU - Belletti, Barbara

AU - Schiappacassi, Monica

AU - Baldassarre, Gustavo

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. However, acquired resistance to platinum occurs frequently and predicts poor prognosis. To understand the mechanisms underlying acquired platinum-resistance, we have generated and characterized three platinum-resistant isogenic EOC cell lines. Resistant cells showed 3-To 5-folds increase in platinum IC50. Cross-resistance to other chemotherapeutic agents commonly used in the treatment of EOC patients was variable and dependent on the cell line utilized. Gene expression profiling (GEP) of coding and non-coding RNAs failed to identify a common signature that could collectively explain the mechanism of resistance. However, we observed that all resistant cell lines displayed a decreased level of DNA platination and a faster repair of damaged DNA. Furthermore, all platinum resistant cell lines displayed a change in their morphology and a higher ability to grown on mesothelium. Overall, we have established and characterized three new models of platinum-resistant EOC cell lines that could be exploited to further dissect the molecular mechanisms underlying acquired resistance to platinum. Our work also suggests that GEP studies alone, at least when performed under basal culture condition, do not represent the optimal way to identify molecular alterations linked to DNA repair pathway defects.

AB - Standard of care for Epithelial Ovarian Cancer (EOC) patients relies on platinum-based therapy. However, acquired resistance to platinum occurs frequently and predicts poor prognosis. To understand the mechanisms underlying acquired platinum-resistance, we have generated and characterized three platinum-resistant isogenic EOC cell lines. Resistant cells showed 3-To 5-folds increase in platinum IC50. Cross-resistance to other chemotherapeutic agents commonly used in the treatment of EOC patients was variable and dependent on the cell line utilized. Gene expression profiling (GEP) of coding and non-coding RNAs failed to identify a common signature that could collectively explain the mechanism of resistance. However, we observed that all resistant cell lines displayed a decreased level of DNA platination and a faster repair of damaged DNA. Furthermore, all platinum resistant cell lines displayed a change in their morphology and a higher ability to grown on mesothelium. Overall, we have established and characterized three new models of platinum-resistant EOC cell lines that could be exploited to further dissect the molecular mechanisms underlying acquired resistance to platinum. Our work also suggests that GEP studies alone, at least when performed under basal culture condition, do not represent the optimal way to identify molecular alterations linked to DNA repair pathway defects.

UR - http://www.scopus.com/inward/record.url?scp=85026833893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026833893&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-07005-1

DO - 10.1038/s41598-017-07005-1

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 7104

ER -